DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug

Bingxue Yang; Xinran Xie; Zhaoyu Wu; Dazhao Lv; Jiajun Hu; Yuyun Chen; Jiaxing Li; Shuyue Luo; Jiacheng Li; Jie Luo; Shiyi Zhang

doi:10.1016/j.gendis.2022.10.004

您当前的位置：

首页 >

文章列表页 >

DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug

Full Length Articles | 更新时间：2024-02-04

- DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug
- DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug
- Genes & Diseases 2023年1卷第6期页码：2557-2571
- 作者机构：
  
  1. School of Pharmacy, Shanghai Jiao Tong University,Shanghai,China,200240
  2. School of Pharmacy and School of Biomedical Engineering, Shanghai Jiao Tong University,Shanghai,China,200240
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.10.004
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug[J]. Genes & Diseases, 2023,1(6):2557-2571.

Bingxue Yang, Xinran Xie, Zhaoyu Wu, et al. DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug[J]. Genes & Diseases, 2023,1(6):2557-2571.
DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug[J]. Genes & Diseases, 2023,1(6):2557-2571. DOI： 10.1016/j.gendis.2022.10.004.

Bingxue Yang, Xinran Xie, Zhaoyu Wu, et al. DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug[J]. Genes & Diseases, 2023,1(6):2557-2571. DOI： 10.1016/j.gendis.2022.10.004.

摘要

Abstract

Hand-foot syndrome (HFS) is a widely recognized dose-limiting cutaneous toxicity effect of fluoropyrimidine chemotherapy agents that impairs clinical benefits and treatment outcomes. Even though the cause and pathophysiology of HFS are relatively widely reported

how the toxicity of fluoropyrimidine translates into persistent inflammation has not been studied. Additionally

prevention and treatment strategies for HFS based on its mechanistic occurrence and development are scarce. In our study

we demonstrated that cGAS-STING signaling pathway-mediated cellular senescence played a critical role in the inflammatory reaction and provided a therapeutic solution for HFS. Mechanistically

DNA damage

as the primary cytotoxic cause

in keratinocytes induces cell cycle arrest

activates the cGAS-STING signaling pathway

and subsequently mediates cellular senescence

ultimately fueling a robust secondary inflammatory response that results in HFS. More importantly

the thymidine prodrug thymidine diacetate was proven to be effective in preventing HFS by compensating for thymidylate deficiency to facilitate the replication and repair of DNA and thus causing the escape from cellular senescence. These data highlight the importance of DNA damage-mediated cellular senescence in the etiology of HFS and provide a potential therapeutic anchor point for fluoropyrimidine-induced HFS.

关键词

Keywords

Cellular senescencecGAS-STINGCutaneous toxicityDNA damageFluoropyrimidineHand-foot syndromeKeratinocytesThymidine prodrug

references

1 C. Heidelberger, N.K. Chaudhuri, P. Danneberg, et al.Fluorinated pyrimidines, A new class of tumour-inhibitory compounds Nature, 179 (4561) (1957), pp. 663-666

2 E. Van Cutsem, C. Twelves, J. Cassidy, et al.Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol, 19 (21) (2001), pp. 4097-4106

3 I. Chau, A.R. Norman, D. Cunningham, et al.A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer Ann Oncol, 16 (4) (2005), pp. 549-557

4 H.S. Son, W.Y. Lee, W.S. Lee, et al.Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy Yonsei Med J, 50 (6) (2009), pp. 796-802

5 Y.S. Heo, H.M. Chang, T.W. Kim, et al.Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy J Clin Pharmacol, 44 (10) (2004), pp. 1166-1172

6 A. Degen, M. Alter, F. Schenck, et al.The hand-foot-syndrome associated with medical tumor therapy - classification and management J Dtsch Dermatol Ges, 8 (9) (2010), pp. 652-661

7 National Cancer Institute, Cancer Therapy Evaluation ProgramCommon terminology criteria for adverse events (CTCAE) version 4.03 (2010)

8 J. Cassidy, C. Twelves, E. van Cutsem, et al.First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin Ann Oncol, 13 (4) (2002), pp. 566-575

9 J.J.M. Kwakman, L.H.J. Simkens, J.M. van Rooijen, et al.Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group Ann Oncol, 28 (6) (2017), pp. 1288-1293

10 Y.S. Hong, Y.S. Park, H.Y. Lim, et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial Lancet Oncol, 13 (11) (2012), pp. 1125-1132

11 E.D. Milligan, K.K. Mehmert, J.L. Hinde, et al.Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120 Brain Res, 861 (1) (2000), pp. 105-116

12 S. Suzuki, S. Nawata, Y. Inada, et al.A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment Mol Clin Oncol, 9 (4) (2018), pp. 443-448

13 Y. Lassere, P. HoffManagement of hand-foot syndrome in patients treated with capecitabine (Xeloda) Eur J Oncol Nurs, 8 (Suppl 1) (2004), pp. S31-S40

14 S.M. Gressett, B.L. Stanford, F. HardwickeManagement of hand-foot syndrome induced by capecitabine J Oncol Pharm Pract, 12 (3) (2006), pp. 131-141

15 P. Narasimhan, S. Narasimhan, I.F. Hitti, et al.Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature Cutis, 73 (2) (2004), pp. 101-106

16 M. Chen, J. Chen, X. Peng, et al.The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome Environ Toxicol Pharmacol, 49 (2017), pp. 81-88

17 S. Latif, G. Fraga, J. GadziaIncreased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding J Drugs Dermatol JDD, 9 (3) (2010), pp. 268-270

18 K.K. Miller, L. Gorcey, B.N. McLellanChemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management J Am Acad Dermatol, 71 (4) (2014), pp. 787-794

19 D.W. Kufe, P.P. Major5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity J Biol Chem, 256 (19) (1981), pp. 9802-9805

20 H.S. Pettersen, T. Visnes, C.B. Vågbø, et al.UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation Nucleic Acids Res, 39 (19) (2011), pp. 8430-8444

21 A.F. Sobrero, C. Aschele, J.R. BertinoFluorouracil in colorectal cancer: a tale of two drugs: implications for biochemical modulation J Clin Oncol, 15 (1) (1997), pp. 368-381

22 C. Aschele, A. Sobrero, M.A. Faderan, et al.Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res, 52 (7) (1992), pp. 1855-1864

23 A. Guglielmi, C. Aschele, F. Grossi, et al.Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients Cytotechnology, 19 (3) (1996), pp. 215-219

24 A.F. Sobrero, C. Aschele, A.P. Guglielmi, et al.Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells J Natl Cancer Inst, 85 (23) (1993), pp. 1937-1944

25 R.I. Glazer, L.S. LloydAssociation of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture Mol Pharmacol, 21 (2) (1982), pp. 468-473

26 G.W. Aherne, A. Hardcastle, F. Raynaud, et al.Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells Biochem Pharmacol, 51 (10) (1996), pp. 1293-1301

27 P.M. Hoff, J. Cassidy, H.J. SchmollThe evolution of fluoropyrimidine therapy: from intravenous to oral Oncol, 6 (S4) (2001), pp. 3-11

28 L. Chintala, S. Vaka, J. Baranda, et al.Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now? Onco Rev, 5 (2) (2011), pp. 129-140

29 M.A.G.I. Cancer, E. Lévy, P. Piedbois, et al.Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors J Clin Oncol, 16 (11) (1998), pp. 3537-3541

30 C. López-Otín, M.A. Blasco, L. Partridge, et al.The hallmarks of aging Cell, 153 (6) (2013), pp. 1194-1217

31 O. Surova, B. ZhivotovskyVarious modes of cell death induced by DNA damage Oncogene, 32 (33) (2013), pp. 3789-3797

32 J.P. Coppé, C.K. Patil, F. Rodier, et al.Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor PLoS Biol, 6 (12) (2008), pp. 2853-2868

33 R. Zhu, X. Ji, X. Wu, et al.Melatonin antagonizes ovarian aging via YTHDF2-MAPK-NF-κB pathway Genes Dis, 9 (2) (2022), pp. 494-509

34 P.L.J. de KeizerThe fountain of youth by targeting senescent cells? Trends Mol Med, 23 (1) (2017), pp. 6-17

35 D. Carli, M. Honorat, S. Cohen, et al.Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS J Chromatogr, B: Anal Technol Biomed Life Sci, 877 (27) (2009), pp. 2937-2944

36 X. Cahours, T.T. Tran, N. Mesplet, et al.Analysis of intracellular didanosine triphosphate at sub-ppb level using LC-MS/MS J Pharm Biomed Anal, 26 (5–6) (2001), pp. 819-827

37 T. Li, Z.J. ChenThe cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer J Exp Med, 215 (5) (2018), pp. 1287-1299

38 Z. Wang, J. Chen, J. Hu, et al.cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity J Clin Invest, 129 (11) (2019), pp. 4850-4862

39 J. Marill, N. Mohamed Anesary, S. ParisDNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells Radiother Oncol, 141 (2019), pp. 262-266

40 M. Demaria, M.N. O'Leary, J. Chang, et al.Cellular senescence promotes adverse effects of chemotherapy and cancer relapse Cancer Discov, 7 (2) (2017), pp. 165-176

41 B. Wang, J. Kohli, M. DemariaSenescent cells in cancer therapy: friends or foes? Trends Cancer, 6 (10) (2020), pp. 838-857

42 H. Yang, H. Wang, J. Ren, et al.cGAS is essential for cellular senescence Proc Natl Acad Sci USA, 114 (23) (2017), pp. E4612-E4620

43 T. Ohnuma, J. Roboz, S. Waxman, et al.Clinical pharmacologic effects of thymidine plus 5-FU Cancer Treat Rep, 64 (12) (1980), pp. 1169-1177

44 H. Madoc-Jones, W.R. BruceOn the mechanism of the lethal action of 5-fluorouracil on mouse L cells Cancer Res, 28 (10) (1968), pp. 1976-1981

45 W.J. Reeves Jr., R. CailleauMechanism of growth inhibition by 5-fluorouracil. Reversal studies with pyrimidine metabolites in vitro Proc Soc Exp Biol Med, 131 (3) (1969), pp. 1068-1072

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Cellular senescence-driven transcriptional reprogramming of the MAFB/NOTCH3 axis activates the PI3K/AKT pathway and promotes osteosarcoma progression

Histone post-translational modification and the DNA damage response